Nonetheless, the increased proliferation and migration due to PRL-3, and the increased expression of PRL-3 mRNA in malignant samples from cancer patients, indicates that PRL-3 inhibition could be a reasonable strategy in prostate cancer treatment. This evidence concerns the gene PTP4A3 and Familial prostate cancer.